BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,753,519 | +106.7% | 938,700 | +34.9% | 0.02% | +110.0% |
| Q2 2023 | $11,972,782 | -2.4% | 696,092 | -5.9% | 0.01% | -9.1% |
| Q1 2023 | $12,269,067 | +76.3% | 739,992 | -19.0% | 0.01% | +83.3% |
| Q4 2022 | $6,959,285 | -32.5% | 913,292 | -12.0% | 0.01% | -40.0% |
| Q3 2022 | $10,315,000 | +7.9% | 1,037,730 | -1.4% | 0.01% | +11.1% |
| Q2 2022 | $9,560,000 | -16.8% | 1,052,830 | -7.0% | 0.01% | 0.0% |
| Q1 2022 | $11,493,000 | -34.4% | 1,132,350 | +7.8% | 0.01% | -25.0% |
| Q4 2021 | $17,526,000 | -18.9% | 1,050,740 | +128.0% | 0.01% | -20.0% |
| Q3 2021 | $21,601,000 | -20.7% | 460,860 | +3.1% | 0.02% | -16.7% |
| Q2 2021 | $27,241,000 | +24.5% | 446,860 | +25.8% | 0.02% | +20.0% |
| Q1 2021 | $21,883,000 | – | 355,237 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |